Can X4 Pharmaceuticals(NASDAQ:XFOR) Transform Chronic Neutropenia Treatment with Its 4WARD and 4STEPS Trials?

Sonal Goyal

05 November 2026 07:54 PM AEDT

Can X4 Pharmaceuticals(NASDAQ:XFOR) Transform Chronic Neutropenia Treatment with Its 4WARD and 4STEPS Trials?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• The 4WARD Phase 3 trial in primary chronic neutropenia is expected to complete target enrollment of 126 participants by the end of Q4 2026, with topline data expected in Q1 2028

• X4 initiated the 4STEPS Phase 2b trial to evaluate G-CSF dose reduction with mavorixafor, with first enrollment expected in Q1 2027

• Cash, cash equivalents, and marketable securities stood at $187.7 million as of September 30, 2026, providing runway into Q1 2029

• Market research presented at Investor Day identified approximately 15,000 to 30,000 U.S. patients in the addressable population for mavorixafor

X4 Pharmaceuticals(NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, reported financial results for the third quarter ended September 30, 2026 and provided a corporate update. The company is advancing mavorixafor through multiple clinical programs targeting primary chronic neutropenia.

4WARD Trial Approaches Full Enrollment

The company's global 4WARD Phase 3 trial of mavorixafor in primary chronic neutropenia continues to advance toward its enrollment target. X4 expects to complete the target enrollment of 126 participants by the end of Q4 2026, with topline data anticipated in Q1 2028. A positive outcome from a Type C meeting with the U.S. FDA led to an optimized trial size while maintaining adequate overall power for the trial's co-primary endpoints of absolute neutrophil count at 93% power and annualized infection rate at 89% power for the intent-to-treat population. Executive Chairman Adam Craig stated that with topline data from both the 4WARD trial and the 4STEPS trial expected in Q1 2028, the company believes mavorixafor is uniquely positioned in the treatment landscape for patients with primary chronic neutropenia. A potential FDA approval could come in late 2028 or early 2029, pending the trial outcome.

4STEPS Phase 2b Trial Design

X4 introduced the 4STEPS trial, a planned Phase 2b study in approximately 25 patients designed to evaluate whether G-CSF dosage can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts. The first participant is expected to be enrolled in Q1 2027, with topline data expected in Q1 2028. At a virtual Investor Day, the company presented market research that identified approximately 15,000 U.S. patients mirroring the 4WARD trial population, with potential upside to approximately 30,000 patients, subject to FDA labeling. The company also secured a senior term Loan Facility of up to $150 million with K2 HealthVentures LLC, replacing a prior loan agreement and providing additional financial flexibility.

Financial Results for Q3 2026

Revenue for Q3 2026 was $2.9 million, including $2.8 million in net product sales attributable to XOLREMDI in the United States, plus $0.1 million in license and other revenue. For the nine months ended September 30, 2026, total Revenue was $14.4 million, which included $6.8 million in license revenue from the Norgine agreement. Research and Development expenses were $13.3 million for the quarter, down from $17.3 million in the prior-year period. Selling, general, and administrative expenses were $14.7 million, compared to $14.5 million in Q3 2025. Net loss attributable to common stockholders was $24.3 million, or $0.26 per diluted share, compared to a net loss of $30.8 million, or $0.39 per diluted share, in Q3 2025. As of September 30, 2026, the company held $187.7 million in cash, cash equivalents, and marketable securities, which it expects to provide a cash runway into Q1 2029.

The Path Forward

X4 Pharmaceuticals' Q3 2026 update highlights the approaching enrollment completion of the 4WARD trial and the initiation of the complementary 4STEPS study. With cash runway extending into Q1 2029 and the secured $150 million term loan facility, the company has positioned its Balance Sheet to support clinical development through anticipated data readouts. The addressable market of 15,000 to 30,000 U.S. patients identified through market research will be a key consideration as the company plans for potential commercialization, subject to FDA labeling outcomes.

FAQs

Q: What is mavorixafor being developed for?

A: Mavorixafor is being developed by X4 Pharmaceuticals for the treatment of primary chronic neutropenia, a rare hematology condition characterized by persistently low neutrophil counts.

Q: When is topline data from the 4WARD trial expected?

A: Topline data from the 4WARD Phase 3 trial is expected in the first quarter of 2028, with a potential FDA approval in late 2028 or early 2029.

Q: What is the 4STEPS trial?

A: 4STEPS is a Phase 2b trial in approximately 25 patients designed to evaluate whether G-CSF dosage can be safely reduced after starting mavorixafor while maintaining stable neutrophil counts.

Q: What is X4's cash runway?

A: As of September 30, 2026, X4 held $187.7 million in cash, cash equivalents, and marketable securities, providing a cash runway into Q1 2029.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.